Paroxetine vs pregabalin for the management of neuropathic pain in multiple sclerosis

Table 3 Study patient characteristics

	Total	Paroxetine	Pregabalin	P value
n	22	10	11	N/A
Demographic
Age: mean (SD)	45.7(12.49)	43.1(12.85)	48.1(12.28)	0.374
Sex: % female	81	90	72.7	NS
Clinical
EDSS: mean (SD)	2.3(1.44)	2.6(1.29)	1.9(1.57)	0.34
Baseline pain: mean (SD)	71.5(10.66)	68.3(10.11)	74.7(10.73)	0.19
Duration of pain (mo): mean (SD)	25.75(19.77)	22.5(19.72)	29(20.31)	0.48
Time since MS diagnosis (yr): mean (SD)	9.39(8.63)	7.8(8.79)	11.38(8.57)	0.4
Analysis
% withdrawal from study	40.9	70	18.2	< 0.001
Average final daily dose (mg) attained (% of maximum possible)	N/A	31 (62)	422.7 (70.5)	N/A

Baseline characteristics–categorized as either “demographic” or “clinical” are presented collectively for all patients combined (n = 22) as well as individually for paroxetine (n = 10) and pregabalin (n = 11) patient groupings. Where appropriate, mean and SD are provided. “Analysis” subheading provides information on the number of patients who withdrew prematurely from the study (“% withdrawal from study”) by group as well as the final average daily dose attained in each group. P values have been provided to estimate equivalence of groups. EDSS: Expanded disability status scale; NS: No significant; N/A: Not available.